Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1–induced platelet reactivity
Science Translational Medicine · 2025
DOI: 10.1126/scitranslmed.ado0610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2025. Verfasst von Philipp Mourikis und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, Heinrich Heine University Medical Center Dusseldorf, 40225 Dusseldorf,…. Hauptthemen laut MEDLINE: Cyclooxygenase 1, Thrombosis, Eicosapentaenoic Acid, Blood Platelets. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Large, randomized trials testing omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation to reduce cardiovascular events have reported contradictory results. Interpretation of these trials is challenging, because different dosages and formulations of ω-3 PUFA were tested. Furthermore, the exact mechanisms for the reduction in cardiovascular events are unclear. In this study, we investigated the effects of ω-3 PUFA on platelet adhesion, degranulation, and aggregation in vitro and in patients with cardiovascular disease using different formulations of ω-3 PUFA. We also investigated the effects of ω-3 PUFA in rodent models of arterial thrombosis and in tail bleeding assays, including in cyclooxygenase-1 (COX-1)–deficient animals. The ω-3 PUFA eicosapentaenoic acid (EPA) dose-dependently reduced platelet adhesion, degranulation, and aggregation in vitro. Moreover, arterial thrombus formation in wild-type mice was inhibited by oral EPA administration before thrombus formation. Photoaffinity labeling and in silico docking analyses suggested a direct, competitive interaction of EPA and arachidonic acid at the level of COX-1. The COX-1 dependency of EPA’s inhibitory effects was confirmed by platelet-specific COX-1–deficient animals that had no reduction of thrombus burden by EPA. In patients with cardiovascular disease, switching from 2 grams of EPA twice daily to 1 gram of docosahexaenoic acid (DHA) (460 milligrams of EPA and 380 milligrams of DHA) once daily completely blunted the platelet inhibition achieved by EPA. Our results may partially explain contradictory results with different ω-3 PUFA formulations in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, Heinrich Heine University Medical Center Dusseldorf, 40225 Dusseldorf, Germany.
- Institute of Analytical Chemistry, University of Vienna, 1090 Vienna, Austria.
- Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., 44227 Dortmund, Germany.
- Department of Anesthesiology, Medical Faculty, Heinrich Heine University Medical Center Dusseldorf, 40225 Dusseldorf, Germany.
- Cardiovascular Research Institute Düsseldorf (CARID), 40225 Düsseldorf, Germany.
- Institute for Clinical Pharmacology, University Medical Center, Georg-August University, Göttingen, 37027 Göttingen, Germany.
ORCID-Profile: Philipp Mourikis, Marcel Benkhoff, Carolin Helten, Amin Polzin
Zitieren
APA
Mourikis, P., Benkhoff, M., Wildeis, L., Barcik, M., Helten, C., Coman, C., Solari, F. A., Krahn, D., Dannenberg, L., Ahlbrecht, S., Zikeli, D., Utz, A., Trojovsky, K., Richter, H., Al Kassis, G., M'Pembele, R., Zako, S., Huckenbeck, T., Bauer, S., …, & Polzin, A. (2025). Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1–induced platelet reactivity. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.ado0610
Vancouver
Mourikis P, Benkhoff M, Wildeis L, Barcik M, Helten C, Coman C, et al. Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1–induced platelet reactivity. Science Translational Medicine. 2025. doi:10.1126/scitranslmed.ado0610
BibTeX
@article{Mourikis2025,
author = {Mourikis, Philipp and Benkhoff, Marcel and Wildeis, Laura and Barcik, Maike and Helten, Carolin and Coman, Cristina and Solari, Fiorella A and Krahn, Daniel and Dannenberg, Lisa and Ahlbrecht, Samantha and Zikeli, Dorothee and Utz, Amelie and Trojovsky, Kajetan and Richter, Hannah and Al Kassis, Gabrielle and M'Pembele, René and Zako, Saif and Huckenbeck, Tim and Bauer, Sofia and Schmitz, Danny and Pfeiler, Susanne and Gerdes, Norbert and Dücker, Christof and Pircher, Joachim and Zhe, Zhang and Thienel, Manuela and Ul Ain, Qurrat and Keul, Petra and Kirkby, Nicholas and Sohn, Dennis and Budach, Wilfried and Hohlfeld, Thomas and Schrör, Karsten and Levkau, Bodo and Zeus, Tobias and Verhelst, Steven H L and Ahrends, Robert and Sickmann, Albert and Mitchell, Jane and Mora, Samia and Manson, JoAnn E and Bhatt, Deepak L and Landmesser, Ulf and Massberg, Steffen and Kelm, Malte and Petzold, Tobias and Polzin, Amin},
title = {Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1–induced platelet reactivity},
journal = {Science Translational Medicine},
year = {2025},
doi = {10.1126/scitranslmed.ado0610}
}
EUVIMED